Table 2 Hazard ratios and 95% confidence intervals for the incidence of end-stage renal disease by quartiles of baseline gamma-glutamyl transferase and average successive variability of gamma-glutamyl transferase.

	Events (n)	Follow-up duration (person-years)	Incidence rate (per 1,000 person-years)	Model 1	Model 2	Model 3
Baseline GGT quartiles^a
Q1 (n = 1,593,642)	3,254	10,166,664.8	0.32	1(Ref.)	1(Ref.)	1 (Ref.)
Q2 (n = 1,429,570)	2,726	9,141,060.0	0.30	0.95 (0.90–1.00)	0.86 (0.82–0.91)	1.06 (1.00–1.11)
Q3 (n = 1,519,057)	3,029	9,716,606.0	0.31	0.99 (0.94–1.04)	0.81 (0.77–0.85)	1.11 (1.06–1.17)
Q4 (n = 1,516,726)	3,048	9,638,948.5	0.32	1.08 (1.03–1.14)	0.76 (0.72–0.80)	1.15 (1.09–1.21)
P for trend				< 0.001	< 0.001	< 0.001
GGT ASV quartiles^b
Q1 (n = 1,515,267)	2,405	9,645,912.3	0.25	1(Ref.)	1(Ref.)	1 (Ref.)
Q2 (n = 1,514,102)	2,649	9,732,995.2	0.27	1.08 (1.02–1.14)	1.03 (0.97–1.09)	1.01 (0.95–1.07)
Q3 (n = 1,514,878)	3,043	9,705,782.5	0.31	1.23 (1.17–1.30)	1.09 (1.04–1.15)	1.06 (1.01–1.12)
Q4 (n = 1,514,748)	3,960	9,578,589.3	0.41	1.59 (1.52–1.68)	1.27 (1.21–1.34)	1.12 (1.06–1.18)
P for trend				< 0.001	< 0.001	< 0.001

GGT, gamma-glutamyl transferase; ASV, average successive variability.
^aQ1: 4–22 (men), 4–14 (women) U/L; Q2: 23–31(men), 15–18 (women) U/L; Q3: 32–50 (men), 19–25 (women) U/L; Q4: 51–1,000 (men), 26–1,000 (women) U/L.
^bQ1: 1–1.16 (men), 1–1.15 (women) U/L; Q2: 1.16–1.27 (men), 1.15–1.26 (women) U/L; Q3: 1.27–1.45 (men), 1.26–1.45 (women) U/L; Q4: 1.45–79.47 (men), 1.45–76.59 (women) U/L. Model 1 is adjusted for age, sex, baseline estimated glomerular filtration rate and body mass index. Model 2 is the same as model 1 plus adjustments for moderate drinking, current smoking, regular exercise, and presence of diabetes, hypertension, and dyslipidemia. Model 3 is the same as model 2 plus adjustments for hemoglobin and an income in the lowest 20%. Additionally, baseline GGT was adjusted in the GGT ASV quartiles.

Search